Ayala Pharmaceuticals’ preclinical data supports clinical development of AL101 in TripleNegative Breast Cancer (TNBC) tumors bearing Notch mutation
– Ongoing Phase 2 ACCURACY study to explore AL101 and its effect on tumor growth inhibition in people with Adenoid
The global pulmonary embolism therapeutics market is expected to post aCAGR of more than 9% during the period 2019-2023, according to thelatest market research report by Technavio.
The traditional R&D in the biopharmaceutical industry iswitnessing an upsurge, due to drug development research, which ishelping in the augmentation of the industrial microbiology market.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) todayannounced the launch of a generic version of Delzicol®1(mesalamine) delayed-release capsules, 400 mg, in the U.S.
Global oligonucleotide synthesis market is expected to reach $2.9billion by 2024, at a CAGR of 10.5% during the forecast period of 2019to 2024.
The global influenza vaccines market size is expected to surpass USD 6billion by 2025.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has launched a generic version of Tarceva®1(erlotinib) tablets, 100 and 150 mg, in the U.S.
Due to an increase in the incidence of medical ailments, the marketstudied is expected to grow over the forecast period.
The $3.12Bn Global Food Enzymes Market by Source, Type, Form, Application and Geography – Forecast to 2024
The global food enzymes market is expected to grow at a CAGR of 7.5%from 2019 to reach $3,125.1 million by 2024 from $2,176.9 million in2019.
Takeda sells Xiidra to Novartis for up to$5.3 billion, TachoSil to Ethicon for approximately $400 million